MedTrace Logo

Platelet REactivity in Sepsis Syndrome (PRESS)

NCT02562261 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 140

Last updated 2018-10-23

No results posted yet for this study

Summary

Activation of blood platelets is a typical finding in patients with systemic inflammation and sepsis.They seem to mediate key pro-inflammatory mediator secretion, immune-cell activation while their adhesion to the endothelium enhances the pro-coagulatory activity of endothelial cells impairing microcirculation thus, may lead to multiple organ dysfunction. However, the exact effects of bacterial products on platelet function have not been found to be consistent and may vary according to the species, the timing of the study, and the pathogenesis of sepsis. Data vary, including both increased and decreased platelet reactivity and aggregation among patients with sepsis compared to healthy controls. Defining platelet's behaviour during sepsis is particularly important in view of recent findings revealing potential association between antiplatelet therapy and reduction in short term mortality, incidence of acute lung injury and intensive care unit admission in critically ill patients.This study aims to measure P2Y12 mediated platelet reactivity, -using the point-of-care P2Y12 VerifyNow assay, in platelet reactivity units (PRU)- along different stages of sepsis, including bacteremia/uncomplicated infection, sepsis, severe sepsis and septic shock. Subgroup follow up of patients going along different stages will also be performed. At the end of this study analysis of clinical and laboratory findings in correlation with platelet reactivity will be performed to assess platelet aggregation during sepsis.

Conditions

  • Sepsis Syndrome

Sponsors & Collaborators

  • Hellenic Society for Chemotherapy : Hellenic Sepsis Study Group

    collaborator UNKNOWN

  • University Hospital of Patras

    collaborator OTHER

  • Charalambos .A. Gogos

    lead OTHER

Principal Investigators

  • Charalampos Gogos, MD,PhD · University Hospital of Patras

  • Karolina Akinosoglou, MD,PhD · University Hospital of Patras

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02562261 on ClinicalTrials.gov